Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early PCSK9 Inhibitor (Alirocumab) in Acute Myocardial Infarction
NCT04731155Phase 4Recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Apr 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of alirocumab in acute myocardial infarction (AMI), sponsored by Shanghai Tongren Hospital. Started Apr 2021; status: recruiting.
02
Drugs
alirocumab
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT04731155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731155.